Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Journal of clinical oncology, 2018-08, Vol.36 (24), p.2465-2472 [Peer Reviewed Journal]ISSN: 0732-183X ;ISSN: 1527-7755 ;EISSN: 1527-7755 ;DOI: 10.1200/jco.2018.78.9909 ;PMID: 29860922
Full text available